While it might make you feel uneasy to invest in a wounded business, it’s worth doing at least once to gain experience, not to mention the chance of a tidy return. After all, if companies never faltered, it’d be impossible to find stocks to buy at a discount in hopes of a skillful turnaround.
In the world of biotech, sometimes turnarounds can happen overnight — and that’s exactly what I’ll be discussing today. These two companies face forks in the road in April that will determine their future, whether it’s a return to good fortune or a further descent into their recent doldrums. Let’s dive in.